# A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease

> **NCT03916042** · PHASE2 · COMPLETED · sponsor: **Aldeyra Therapeutics, Inc.** · enrollment: 206 (actual)

## Conditions studied

- Dry Eye

## Interventions

- **DRUG:** Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID
- **DRUG:** Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID

## Key facts

- **NCT ID:** NCT03916042
- **Lead sponsor:** Aldeyra Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-23
- **Primary completion:** 2019-11-22
- **Final completion:** 2019-11-22
- **Target enrollment:** 206 (ACTUAL)
- **Last updated:** 2025-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03916042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03916042, "A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03916042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*